



INCan
Mexico



INNN
Mexico

INTERINSTITUTIONAL COLLABORATION TO DELIVER NEUROAXIS RADIOTHERAPY AND STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES IN MEXICO: EXPERIENCE FROM TWO NATIONAL REFERENCE CENTERS

Alejandro Rodríguez Camacho¹, Sergio Moreno-Jiménez¹, Guillermo Gutiérrez-Aceves¹, Enrique Caballe Pérez², Bernardo Cacho Díaz², Mónica Serrano Murillo², Talía Wegman Ostrosky², Alberto González Aguilar², José Herrera-González², Miguel Celis-López¹, Dharely Cid Sánchez², Federico Maldonado Mago², Alipio González Vázquez², Óscar Arrieta-Rodríguez²
National Institute of Neurology and Neurosurgery¹; INCan, Mexico City, Mexico²

ISRS 2026

SYDNEY, AUSTRALIA

31ST MAY - 3RD JUNE

PROGRAM AT A GLANCE

66

patients referred

156

metastases treated

18

SRS targets at INCan

22

primary CNS referrals

3.10

median volume cm³

CLINICAL GAP AND OBJECTIVE

Fragmented national reference centers may limit access to CNS radiosurgery, neuroaxis chemoradiotherapy and molecular diagnostics.

Objective: implement a formal bidirectional pathway to expand QA-driven intracranial SRS and coordinate neuroaxis care.


QUALITY AND SAFETY WORKFLOW

- Multidisciplinary indication review
- Contouring and plan peer review
- Independent physics checks
- Patient-specific QA
- Image-guided delivery and coordinated follow-up

SRS ELIGIBILITY CRITERIA

- Controlled extracranial disease
- KPS >70
- 1-10 brain metastases or cumulative intracranial tumor volume <=10 cm³

BIDIRECTIONAL PROGRAM MODEL



INCan start-up: commissioning and intracranial SRS delivery

INCAN-TO-INNN SRS COHORT

66 patients referred for SRS at INNN for 156 intracranial metastases.
Age 30-78 years (median 53); 57.1% female.
Median cumulative intracranial volume 3.10 cm³ (IQR 1.39-6.90; range 0.1-105.6).
62.9% originated from Mexico City/State of Mexico.

INCAN SRS START-UP

18

metastatic targets

Through November 2025
7 lung, 6 breast, 5 other


Gynecologic,
colorectal,
sarcoma

7 lung

6 breast

5 other

PRIMARY TUMOR DISTRIBUTION IN INCAN-TO-INNN SRS COHORT



INNN-TO-INCAN NEUROAXIS PATHWAY

22

primary CNS tumor referrals

Referred for neuroaxis chemoradiotherapy and molecular work-up.

Medulloblastoma 13; ependymoma 2; choroid plexus carcinoma 2; embryonal tumors 2; other single histologies 3.

TAKE-HOME: A formal pathway expanded QA-driven intracranial SRS access, enabled INCan SRS implementation, and streamlined complex neuroaxis care with molecular diagnostics.

